BioCorRx Inc
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company offers a substance use disorder recovery program, Beat Addiction Recovery, which includes cognitive behavioral therapy modules, peer support through a mobile application, and medication prescription from an independent treating physician; an… Read more
BioCorRx Inc (BICX) - Total Liabilities
Latest total liabilities as of September 2025: $20.30 Million USD
Based on the latest financial reports, BioCorRx Inc (BICX) has total liabilities worth $20.30 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioCorRx Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how BioCorRx Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioCorRx Inc Competitors by Total Liabilities
The table below lists competitors of BioCorRx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KWESST Micro Systems Inc. Common Stock
NASDAQ:KWE
|
USA | $2.80 Million |
|
Axel Ree Ltd
AU:AXL
|
Australia | AU$230.18K |
|
Arad Ltd
TA:ARD
|
Israel | ILA211.30 Million |
|
LM Funding America Inc
NASDAQ:LMFA
|
USA | $11.75 Million |
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
USA | $804.97K |
|
Phoslock Environmental Technologies Ltd
AU:PET
|
Australia | AU$348.00K |
|
Saranacentral Bajatama Tbk
JK:BAJA
|
Indonesia | Rp638.85 Billion |
|
Destiny Media Technologies Inc
OTCQB:DSNY
|
USA | $496.86K |
Liability Composition Analysis (2014–2024)
This chart breaks down BioCorRx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioCorRx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioCorRx Inc (2014–2024)
The table below shows the annual total liabilities of BioCorRx Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $12.74 Million | +23.21% |
| 2023-12-31 | $10.34 Million | +15.31% |
| 2022-12-31 | $8.97 Million | +15.25% |
| 2021-12-31 | $7.78 Million | +28.89% |
| 2020-12-31 | $6.04 Million | +20.94% |
| 2019-12-31 | $4.99 Million | -21.19% |
| 2018-12-31 | $6.33 Million | +49.69% |
| 2017-12-31 | $4.23 Million | -50.80% |
| 2016-12-31 | $8.60 Million | +83.46% |
| 2015-12-31 | $4.69 Million | +24.12% |
| 2014-12-31 | $3.78 Million | -- |